DIN 02229731 — ORPHENADRINE CITRATE INJECTION, USP 30 MG
ORPHENADRINE CITRATE INJECTION, USP is a liquid of Orphenadrine marketed by STERIMAX INC. The full Orphenadrine monograph covers indications, dosing, interactions and counselling for every strength and manufacturer.
- DIN
- 02229731
- Brand name
- ORPHENADRINE CITRATE INJECTION, USP
- Active ingredient
- Orphenadrine
- Strength
- 30 MG
- Dosage form
- LIQUID
- Route
- INTRAMUSCULAR; INTRAVENOUS
- Manufacturer
- STERIMAX INC
- Health Canada status
- DORMANT
- Drug class
- Centrally acting skeletal muscle relaxant with antimuscarinic (anticholinergic) activity
Product data from the Health Canada Drug Product Database, synced . Verify the live status at Health Canada.
Other Orphenadrine products
| DIN | Brand | Strength | Form | Manufacturer | Status |
|---|---|---|---|---|---|
| 02047535 | ORFENACE TABLET 100MG | 100 MG | TABLET | STERIMAX INC | DORMANT |
| 02243559 | SANDOZ ORPHENADRINE | 100 MG | TABLET (EXTENDED-RELEASE) | SANDOZ CANADA INCORPORATED | MARKETED |